Renovacor (NYSE:RCOR) Downgraded to Neutral at BTIG Research

BTIG Research cut shares of Renovacor (NYSE:RCORGet Rating) from a buy rating to a neutral rating in a report issued on Tuesday morning, The Fly reports.

Other equities research analysts have also issued reports about the company. LADENBURG THALM/SH SH lowered Renovacor from a buy rating to a neutral rating in a research report on Tuesday. Robert W. Baird initiated coverage on shares of Renovacor in a report on Monday, September 12th. They issued an outperform rating on the stock. Finally, Lifesci Capital restated an outperform rating on shares of Renovacor in a research report on Thursday, June 16th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $21.00.

Renovacor Stock Performance

Shares of RCOR opened at $2.18 on Tuesday. Renovacor has a 52-week low of $1.34 and a 52-week high of $10.47. The stock’s 50-day simple moving average is $1.86 and its 200 day simple moving average is $2.65. The stock has a market capitalization of $37.64 million, a price-to-earnings ratio of -2.99 and a beta of 0.09.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Renovacor stock. State Street Corp purchased a new position in shares of Renovacor, Inc. (NYSE:RCORGet Rating) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,829 shares of the company’s stock, valued at approximately $50,000. State Street Corp owned about 0.07% of Renovacor at the end of the most recent reporting period. 45.84% of the stock is currently owned by institutional investors and hedge funds.

About Renovacor

(Get Rating)

Renovacor, Inc, a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM).

See Also

The Fly logo

Analyst Recommendations for Renovacor (NYSE:RCOR)

Receive News & Ratings for Renovacor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovacor and related companies with MarketBeat.com's FREE daily email newsletter.